The genetics of cutaneous melanoma

Clinics in Laboratory Medicine

Volumn 20, Issue 4, 2000, Pages 667-690

  Pollock, P M ^a   Trent, J M ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENE PRODUCT; PROTEIN CDKN2A; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER SUSCEPTIBILITY; CHROMOSOME 10Q; CHROMOSOME 11Q; CHROMOSOME 1P; CHROMOSOME 6Q; CHROMOSOME 7P; CHROMOSOME 9P; CYTOGENETICS; GENE MUTATION; GENE SEQUENCE; GENETIC PREDISPOSITION; HUMAN; MELANOGENESIS; MELANOMA; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; RISK FACTOR; SKIN CANCER; ULTRAVIOLET RADIATION;

CLUSTER ANALYSIS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; DISEASE PROGRESSION; DNA, NEOPLASM; GENES, P16; GERM-LINE MUTATION; HUMANS; MELANOMA; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORIC MONOESTER HYDROLASES; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 0034486175     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. CDKN2A variants in a population-based sample of Queensland families with melanoma
2. Molecular genetics of human malignant melanoma
3. Characteristics of familial and non-familial melanoma in Australia
4. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors
5. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p
6. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis
7. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis
8. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsiesy
9. Molecular classification of cutaneous malignant melanoma by gene expression profiling
10. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22
11. Evidence against the reported linkage of the cutaneous melanoma-dysplastic nevus syndrome locus to chromosome Ip36
12. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
13. CDKN2A/p16 is inactivated in most melanoma cell lines
14. Genomic analysis of metastasis reveals an essential role for RhoC
15. Origin of familial malignant melanomas from heritable melanocytic lesions: The B-K mole syndrome
16. Cytogenefic analysis in melanoma and nevi
17. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas
18. Use of a cDNA microarray to analyse gene expression patterns in human cancer
19. Inherited macrocephaly-hamartoma syndromes
20. Expression profiling using cDNA microarrays
21. A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies
22. The dysplastic nevus syndrome: Our definition
23. Cell cycle checkpoints: Preventing an identity crisis
24. Laser capture microdissection
25. CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds
26. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: Analysis of a clinic-based population
27. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds
28. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma
29. The CDKN2A (p16) gene and human cancer
30. Genetic factors
31. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma
32. A cyclin D-Cdk4 activity required for G2 phase cell cycle progression is inhibited in ultraviolet radiation-induced G 2 phase delay
33. Low frequency of p16/CDKN2A methylation in sporadic melanoma: Comparative approaches for methylation analysis of primary tumors
34. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)
35. Locus for susceptibility to melanoma on chromosome 1p
36. Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families: Effect of naevus count
37. Genetic evidence in melamoma and bladder cancers that p 16 and p53 function in separate pathways of tumor suppression
38. Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: A novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma
39. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma
40. Molecular genetics of familial cutaneous melanoma
41. The current situation with regard to human melanoma and genetic inferences
42. Melanoma susceptibility: Population bases incidence of germline CDKN2A mutations in selected families with cutaneous melanoma
43. Molecular pathology of cutaneous melanoma
44. Infrequent mutation of p16INK4 in sporadic melanoma
45. Further evidence for ultraviolet light induction of CDKN2 (p16INK4) mutations in sporadic melanoma in vivo
46. Loss of heterozygosity for 10q22-10qter in malignant melanoma progression
47. Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma
48. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas
49. p16(INK4a) and the control of cellular proliferative life span
50. Germline p16 mutations in familial melanoma
51. 10q deletions in metastatic cutaneous melanoma
52. Chromosome 10 allelic loss in malignant melanoma
53. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
54. Tumor spectrum in ARF-deficient mice
55. Tumor suppression at the mouse INK 4a locus mediated by the alternative reading frame product p19ARF
56. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium
57. Hereditary melanoma in Australia: Variable association with dysplastic nevi and absence of genetic linkage to chromosome 1p
58. Tissue microarrays for high-throughput molecular profiling of tumor specimens
59. Mutations in the CDKN2A (p16INK4a) gene in microdissected sporadic primary melanomas
60. Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): Homozygous deletions and mutations in the p 16 and p14ARF genes in sporadic primary melanomas
61. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
62. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
63. Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF
64. Familial atypical multiple mole-melanoma syndrome
65. CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas
66. Increasing incidence of cutaneous melanoma in Queensland, Australia
67. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
68. A novel pl6INK4A transcript
69. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan Zonana syndrome, two hamartoma syndromes with germline PTEN mutation
70. Germlinemutations in PTEN are present in Bannayan-Zonana syndrome
71. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome
72. Involvement of p16CDKN2A in cell cycle delays after low dose UV irradiation
73. CDKN2A mutations in multiple primary melanomas
74. Confirmation of chromosome 9p linkage in familial melanoma
75. Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm 1p in 7 Australian pedigrees
76. Localization of the gene for Cowden disease to chromosome 10q22-23
77. Germline mutations in the pTEN/MMAC 1 gene in patients with Cowden disease
78. Mutation testing in melanoma families: INK 4A, CDK4 and INK4D
79. Deletions of the cyclin-dependent kinase- 4 inhibitor gene in multiple human cancers
80. Deletion mapping of chromosome region 9p21p22 surrounding the CDKN2 locus in melanoma
81. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma
82. Possible involvement of the chromosome region 10q24-q26 in early stages of melanocytic neoplasia
83. Ultraviolet radiation induces p16CDKN2A expression in human skin
84. UV fingerprint CDKN2a but no p14ARF mutations in sporadic melanomas
85. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression
86. Melanoma genetics: An update with focus on the CDKN2A(p16)/ARF tumor suppressors
87. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma
88. Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: A clinic-based population study
89. Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma
90. The p53 pathway
91. Chromosome 9p deletions in cutaneous malignant melanoma tumors: The minimal deleted region involves markers outside the p16 (CDKN2) gene
92. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
93. Growth factor and cytogenetic abnormalities in cultured nevi and malignant melanomas
94. Differential expression of p16INK4a and p16beta transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations
95. Multiple abnormalities of the p 16INK4apRb regulatory pathway in cultured melanoma cells
96. Retention of the CDKN2A locus and low frequency of point mutations in primary and metastatic cutaneous malignant melanoma
97. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
98. Tumor surveillance via the ARF-p53 pathway
99. CDK inhibitors: Positive and negative regulators of G1-phase progression
100. Inhibitors of mammalian G1 cyclin-dependent kinases
101. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France: The French Familial Melanoma Study Group
102. Identification of a candidate tumour suppressor gene, MMAC 1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
103. Genomic structure, expression and mutational analysis of the P15 (MTS2) gene
104. Complex structure and regulation of the P16 (MTS1) locus
105. PTEN gene and integrin signaling in cancer
106. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines
107. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene
108. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines
109. Exclusion of the dysplastic nevus syndrome (DNS) locus from the short arm of chromosome 1 by linkage studies in Dutch families
110. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets
111. A genetic model of melanoma tumorigenesis based on allelic losses
112. Accumulation of p16CDKN2A in response to ultraviolet irradiation correlates with late S-G(2)-phase cell cycle delay
113. Germline CDKN2A mutations in childhood melanoma
114. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: The location of a putative tumor suppressor gene
115. A p16INK4a-insensitive CDK 4 mutant targeted by cytolytic T lymphocytes in a human melanoma
116. Germline mutations in the p 16INK4a binding domain of CDK4 in familial melanoma